Post-earnings recap
Reported
Thu, Nov 7, 2024
EPS actual
$0.10
EPS est.
$0.02
EPS surprise
+334.78%
1-day move
+10.90%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Aurinia Pharmaceuticals reported a positive surprise in EPS, which contributed to a 10.9% increase in stock price following the earnings announcement. However, there was no revenue reported, leaving some uncertainty about overall performance. Investors may view the EPS beat as a sign of potential growth, but the lack of guidance and revenue information could temper enthusiasm.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.10 | N/A | +334.78% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.